Merck is investing $30 million in a Series B round of financing for Visterra.
The Series B financing round was co-led by new Visterra investors, Merck Research Labs Venture Fund, Vertex Venture Holdings and Temasek Life Science Ventures.
Existing investors Polaris Partners, Flagship Ventures, Omega Funds and Alexandria Venture Investments, and new investor Cycad Group, also participated in the upsized financing.
Proceeds from the round will be used to advance the development of multiple product candidates from the company’s pipeline of novel monoclonal antibodies that target infectious diseases, including VIS410 for seasonal and pandemic influenza and VIS513 for dengue fever, into the clinic.
For further deal information visit Current Agreements (subscription required)
Read: more on financing deals in pharma, biotech, life science partnering deal news, insights and glossary
Report: Finding Biopharma and Collaboration Partners
Related reports: Entire Current Partnering reports catalog
View: Financing Scorecard in CP Insight – view top life science financing deals by value
View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity